Sanofi Adr Stock Probability Of Bankruptcy
| SNY Stock | USD 49.01 0.45 0.91% |
Sanofi | Probability Of Bankruptcy |
Sanofi ADR Company probability of bankruptcy Analysis
Sanofi ADR's Probability Of Bankruptcy is a relative measure of the likelihood of financial distress. For stocks, the Probability Of Bankruptcy is the normalized value of Z-Score. For funds and ETFs, it is derived from a multi-factor model developed by Macroaxis. The score is used to predict the probability of a firm or a fund experiencing financial distress within the next 24 months. Unlike Z-Score, Probability Of Bankruptcy is the value between 0 and 100, indicating the firm's actual probability it will be financially distressed in the next 2 fiscal years.
More About Probability Of Bankruptcy | All Equity Analysis
Probability Of Bankruptcy | = | Normalized | | Z-Score |
Current Sanofi ADR Probability Of Bankruptcy | Less than 3% |
Most of Sanofi ADR's fundamental indicators, such as Probability Of Bankruptcy, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Sanofi ADR is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Our calculation of Sanofi ADR probability of bankruptcy is based on Altman Z-Score and Piotroski F-Score, but not limited to these measures. To be applied to a broader range of industries and markets, we use several other techniques to enhance the accuracy of predicting Sanofi ADR odds of financial distress. These include financial statement analysis, different types of price predictions, earning estimates, analysis consensus, and basic intrinsic valuation. Please use the options below to get a better understanding of different measures that drive the calculation of Sanofi ADR financial health.
Is Sanofi ADR's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sanofi ADR. If investors know Sanofi will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Sanofi ADR listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.43) | Earnings Share 1.94 | Revenue Per Share 18.492 | Quarterly Revenue Growth 0.023 | Return On Assets 0.0454 |
The market value of Sanofi ADR is measured differently than its book value, which is the value of Sanofi that is recorded on the company's balance sheet. Investors also form their own opinion of Sanofi ADR's value that differs from its market value or its book value, called intrinsic value, which is Sanofi ADR's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Sanofi ADR's market value can be influenced by many factors that don't directly affect Sanofi ADR's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Sanofi ADR's value and its price as these two are different measures arrived at by different means. Investors typically determine if Sanofi ADR is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sanofi ADR's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Sanofi Probability Of Bankruptcy Driver Correlations
Understanding the fundamental principles of building solid financial models for Sanofi ADR is extremely important. It helps to project a fair market value of Sanofi Stock properly, considering its historical fundamentals such as Probability Of Bankruptcy. Since Sanofi ADR's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Sanofi ADR's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Sanofi ADR's interrelated accounts and indicators.
Click cells to compare fundamentals
The Probability of Bankruptcy SHOULD NOT be confused with the actual chance of a company to file for chapter 7, 11, 12, or 13 bankruptcy protection. Macroaxis simply defines Financial Distress as an operational condition where a company is having difficulty meeting its current financial obligations towards its creditors or delivering on the expectations of its investors. Macroaxis derives these conditions daily from both public financial statements as well as analysis of stock prices reacting to market conditions or economic downturns, including short-term and long-term historical volatility. Other factors taken into account include analysis of liquidity, revenue patterns, R&D expenses, and commitments, as well as public headlines and social sentiment.
| Competition |
Based on the latest financial disclosure, Sanofi ADR has a Probability Of Bankruptcy of 3.0%. This is 93.07% lower than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The probability of bankruptcy for all United States stocks is 92.47% higher than that of the company.
Sanofi Probability Of Bankruptcy Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Sanofi ADR's direct or indirect competition against its Probability Of Bankruptcy to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Sanofi ADR could also be used in its relative valuation, which is a method of valuing Sanofi ADR by comparing valuation metrics of similar companies.Sanofi ADR is currently under evaluation in probability of bankruptcy category among related companies.
Sanofi ADR Main Bankruptcy Drivers
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Return On Assets | 0.0249 | 0.11 | 0.0518 | 0.0672 | 0.0427 | 0.0773 | |
| Net Debt | 16.5B | 9.8B | 12.3B | 8.5B | 9.7B | 7.6B | |
| Total Current Liabilities | 20.4B | 19.3B | 21.3B | 24.0B | 24.2B | 14.3B | |
| Non Current Liabilities Total | 33.2B | 32.1B | 29.9B | 27.1B | 27.9B | 23.5B | |
| Total Assets | 112.7B | 114.5B | 120.2B | 124.6B | 126.5B | 88.2B | |
| Total Current Assets | 28.9B | 33.8B | 30.7B | 34.1B | 30.7B | 22.0B | |
| Total Cash From Operating Activities | 7.7B | 7.4B | 10.5B | 10.5B | 10.3B | 7.3B |
Sanofi Fundamentals
| Return On Equity | 0.0727 | ||||
| Return On Asset | 0.0454 | ||||
| Profit Margin | 0.1 % | ||||
| Operating Margin | 0.18 % | ||||
| Current Valuation | 71.22 B | ||||
| Shares Outstanding | 2.5 B | ||||
| Shares Owned By Institutions | 10.09 % | ||||
| Number Of Shares Shorted | 3.24 M | ||||
| Price To Earning | 7.78 X | ||||
| Price To Book | 1.44 X | ||||
| Price To Sales | 2.52 X | ||||
| Revenue | 43.07 B | ||||
| Gross Profit | 31.7 B | ||||
| EBITDA | 12.96 B | ||||
| Net Income | 5.4 B | ||||
| Cash And Equivalents | 6.9 B | ||||
| Cash Per Share | 2.76 X | ||||
| Total Debt | 18.42 B | ||||
| Debt To Equity | 0.30 % | ||||
| Current Ratio | 1.30 X | ||||
| Book Value Per Share | 59.17 X | ||||
| Cash Flow From Operations | 10.26 B | ||||
| Short Ratio | 1.71 X | ||||
| Earnings Per Share | 1.94 X | ||||
| Price To Earnings To Growth | 0.84 X | ||||
| Target Price | 58.92 | ||||
| Number Of Employees | 86.09 K | ||||
| Beta | 0.45 | ||||
| Market Capitalization | 122.94 B | ||||
| Total Asset | 126.46 B | ||||
| Retained Earnings | 67.5 B | ||||
| Working Capital | 6.46 B | ||||
| Current Asset | 24.93 B | ||||
| Current Liabilities | 16.82 B | ||||
| Annual Yield | 0.04 % | ||||
| Five Year Return | 3.85 % | ||||
| Net Asset | 126.46 B |
About Sanofi ADR Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Sanofi ADR's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Sanofi ADR using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Sanofi ADR based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
When determining whether Sanofi ADR offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Sanofi ADR's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Sanofi Adr Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Sanofi Adr Stock:Check out Sanofi ADR Piotroski F Score and Sanofi ADR Altman Z Score analysis. For more information on how to buy Sanofi Stock please use our How to Invest in Sanofi ADR guide.You can also try the Options Analysis module to analyze and evaluate options and option chains as a potential hedge for your portfolios.
Complementary Tools for Sanofi Stock analysis
When running Sanofi ADR's price analysis, check to measure Sanofi ADR's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sanofi ADR is operating at the current time. Most of Sanofi ADR's value examination focuses on studying past and present price action to predict the probability of Sanofi ADR's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sanofi ADR's price. Additionally, you may evaluate how the addition of Sanofi ADR to your portfolios can decrease your overall portfolio volatility.
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. |
Is Sanofi ADR's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sanofi ADR. If investors know Sanofi will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Sanofi ADR listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.43) | Earnings Share 1.94 | Revenue Per Share 18.492 | Quarterly Revenue Growth 0.023 | Return On Assets 0.0454 |
The market value of Sanofi ADR is measured differently than its book value, which is the value of Sanofi that is recorded on the company's balance sheet. Investors also form their own opinion of Sanofi ADR's value that differs from its market value or its book value, called intrinsic value, which is Sanofi ADR's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Sanofi ADR's market value can be influenced by many factors that don't directly affect Sanofi ADR's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Sanofi ADR's value and its price as these two are different measures arrived at by different means. Investors typically determine if Sanofi ADR is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sanofi ADR's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.